Compare AbCellera Biologics Inc (ABCL) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Garmin Ltd. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Garmin Ltd. trades at $243.53 (market cap $47.96B). The key difference: Garmin Ltd. is far larger — about 20.4× AbCellera Biologics Inc's market cap, and Garmin Ltd. pays a 1.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GRMN | |
|---|---|---|
Market Cap | $2.35B | $47.96B |
Sector | Health | Technology |
52-Week High | $8.12 | $267.52 |
52-Week Low | $2.78 | $187.10 |
Enterprise Value | $1.99B | $45.43B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Garmin (GRMN) trades at $248.68, up 3.63% today, reflecting strong momentum near its recent highs. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 23.26% net income margin and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent product launches like LiveScope 2 and positive earnings beats in Q4 2025 and Q1 2026 underscore operational strength.
The outlook remains favorable with a consensus price target of $282.67, though risks include competitive pressures and market volatility. Investment appeal centers on sustained profitability and innovation, but investors should weigh high valuation multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
